We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

50 hedge funds and large institutions have $174M invested in Arbutus Biopharma in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

520% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 5

341% more capital invested

Capital invested by funds: $39.5M → $174M (+$135M)

126% more call options, than puts

Call options by funds: $7.7M | Put options by funds: $3.4M

108% more funds holding

Funds holding: 24 → 50 (+26)

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
50
Holders Change
+26
Holders Change %
+108.33%
% of All Funds
1.44%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
31
Increased
11
Reduced
6
Closed
5
Calls
$7.7M
Puts
$3.4M
Net Calls
+$4.29M
Net Calls Change
+$4.29M

Top Buyers

1
Wells Fargo
Wells Fargo
California
+$14.2M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$8.08M
3
BA
BlackRock Advisors
Delaware
+$7.49M
4
SCM
Sigma Capital Management
Connecticut
+$5.39M
5
BIM
Bogle Investment Management
Massachusetts
+$5.3M

Top Sellers

1
SM
Sabby Management
Florida
-$9.33M
2
PC
PointState Capital
New York
-$2.77M
3
OAM
Orinda Asset Management
California
-$407K
4
B
Bailard
California
-$365K
5
BBA
Baker Bros. Advisors
New York
-$285K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
51
Sabby Management
Florida
– -$9.33M -519,200 Closed
PC
52
PointState Capital
New York
– -$2.77M -348,000 Closed
ARTA
53
A.R.T. Advisors
New York
– -$213K -26,832 Closed
SKK
54
Shepherd Kaplan Krochuk
Massachusetts
– -$139K -17,418 Closed
HCM
55
Highlander Capital Management
New Jersey
– -$15.9K -2,000 Closed
1 2
3

ABUS Hedge Fund Activity: Q1 2014 in Review

50 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2014, worth a combined $174M — up 341% from $39.5M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ABUS positions and 5 closed out — a net gain of 26 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was Wells Fargo, opening a new position worth an estimated $14.2M. The largest seller was Sabby Management, exiting entirely with an estimated $9.33M sold.

  • 50 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2014, up from 24 in Q4 2013.
  • Funds reported $174M of Arbutus Biopharma stock for Q1 2014, up 341% quarter-over-quarter.
  • 31 funds opened new Arbutus Biopharma positions in Q1 2014 and 5 closed out, a net change of +26 holders.
  • The largest Arbutus Biopharma buyer in Q1 2014 was Wells Fargo, an estimated $14.2M added.
  • The largest Arbutus Biopharma seller in Q1 2014 was Sabby Management, an estimated $9.33M sold.

Based on aggregated 13F filings for Q1 2014.